EGFR and non-small cell lung carcinoma: Osimertinib has demonstrated systemic efficacy in patients with untreated EGFRm NSCLC, being able to penetrate the blood brain barrier and to achieve a significant exposure in the CNS compared to other EGFR TKIs [15,39].